Tumor–Microbiota Crosstalk: Immune Modulation and Resistance to Cancer Therapies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Infectious Agents and Cancer".
Deadline for manuscript submissions: 25 December 2026 | Viewed by 6
Special Issue Editor
Interests: colorectal cancer; breast cancer; complementary and alternative medicine (CAM); virus and cancer; HIV/AIDS and cancer; prognostic and predictive factors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The gut and tumor-associated microbiota have emerged as critical regulators of cancer development, progression, and therapeutic response. The microbiota can modulate immune responses through several mechanisms, including the production of metabolites such as short-chain fatty acids that shape T cell differentiation, the activation of pattern recognition receptors that trigger innate immune pathways, and the modulation of cytokine networks that influence both local and systemic inflammation. This Special Issue aims to explore the complex interplay among microbial communities, the immune system, and tumor biology, focusing on how these interactions influence chemo- and immunoresistance. Contributions that investigate how these microbial–immune interactions affect cancer progression, therapy resistance, and patient outcomes, as well as strategies for manipulating the microbiota to enhance treatment efficacy, are encouraged. By integrating insights from immunology, oncology, and microbiome research, this Special Issue seeks to highlight novel approaches to overcoming therapeutic resistance and advance microbiota-informed cancer treatment strategies.
Dr. Massimiliano Berretta
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor–microbiota
- immune modulation
- cancer therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
